Mayo Clinic is building toward a future when biologics can cure cancer, kidney disease and diabetes. Mayo marks 2022 as a year of significant strides in accelerating science to make and deliver regenerative biotherapeutics. The goal is to offer new options, based on rigorous research in cell and gene therapies, for disorders with few available treatments.
The Mayo Clinic Center for Regenerative Biotherapeutics has a new strategy of advancing regenerative discoveries toward early-stage clinical trials and industry collaborations.
"Pharmaceuticals at the drugstore often only address the symptoms. With biotherapeutics, we are looking for cures," says Julie Allickson, Ph.D., the Michael S. and Mary Sue Shannon Family Director of Mayo Clinic's Center for Regenerative Biotherapeutics. "We are building an advanced ecosystem of expert physicians, scientists, industry collaborators and advanced facilities to lead the way in providing a new class of medicines, especially for unmet clinical needs."
Dr. Allickson is also the Otto Bremer Trust Director, Biomanufacturing and Product Development, Center for Regenerative Biotherapeutics.
Regenerative biotherapeutics are aimed at restoring damaged tissues, cells and organs that are at the root of most diseases. Mayo's strategy emphasizes therapeutics known as biologics that are derived from human sources, such as blood, tissue, cells, enzymes, genes or genetically engineered cells. Biologics show potential for more targeted healing with fewer side effects than standard pharmaceuticals.
Read the rest of the article on the Center for Regenerative Biotherapeutics blog.
Other Mayo Clinic medical research websites: